Cybin Inc Revenue Growth Rates (CYBN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cybin Inc   (NYSEAMER: CYBN)
 

CYBN's Revenue Growth by Quarter and Year

Cybin Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CYBN/growth
https://api.csimarket.com/api/v1/companies/CYBN/fundamentals
https://api.csimarket.com/api/v1/companies/CYBN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CYBN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June 0.00
FY 0.00





CYBN Revenue first quarter 2026 Y/Y Growth Comment
Cybin Inc in the first quarter 2026 recorded of $ 0.00 millions.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Revenue growth. While Cybin Inc ' s Revenue no change of 0% ranks overall at the positon no. 115 in the first quarter 2026.


CYBN Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June -
FY   -

Financial Statements
Cybin Inc 's first quarter 2026 Revenue $ 0.00 millions CYBN's Income Statement
Cybin Inc 's first quarter 2025 Revenue $ 0.00 millions Quarterly CYBN's Income Statement


CYBN Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June -
FY (Year on Year)   -


Back to CYBN Growth rate Comparisons >> Back to CYBN Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #36
Overall #115

Revenue Y/Y Growth Statistics
High Average Low
123.74 % 123.74 % 123.74 %
(Mar 31 2025)  
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #36
Overall #115
Revenue Y/Y Growth Statistics
High Average Low
123.74 % 123.74 % 123.74 %
(Mar 31 2025)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Cybin Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYBN's I. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Cybin Inc come out even worse considering the 159.15 millions a quarter before.

Within Major Pharmaceutical Preparations industry Cybin Inc achieved highest sequential Revenue growth. While Cybin Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYBN's I. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Cybin Inc come out even worse considering the 159.15 millions a quarter before.

Within Major Pharmaceutical Preparations industry Cybin Inc achieved highest sequential Revenue growth. While Cybin Inc 's Revenue growth quarter on quarter, overall rank is .


Cybin Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending (Mar 31 2024) 12 Months Ending (Mar 31 2023) 12 Months Ending 12 Months Ending
Cumulative Revenue 12 Months Ending $ 159.15
Y / Y Revenue Growth (TTM) 123.74 %
Year on Year Revenue Growth Overall Ranking # 115
Seqeuential Revenue Change (TTM) 123.74 %
Seq. Revenue Growth (TTM) Overall Ranking # 115


Cumulative Revenue growth Comment
With 123.74% annual Revenue growth, Cybin Inc would report a record annual Revenue surge if the fiscal year would end on Mar 31 2025.

In the Healthcare sector 35 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 114 to 115.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 36
Overall # 115

Revenue TTM Y/Y Growth Statistics
High Average Low
123.74 %
 123.74 %
123.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 36
S&P 500 # 115
Cumulative Revenue growth Comment
With 123.74% annual Revenue growth, Cybin Inc would report a record annual Revenue surge if the fiscal year would end on Mar 31 2025.

In the Healthcare sector 35 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 114 to 115.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 36
Overall # 115

Revenue TTM Y/Y Growth Statistics
High Average Low
123.74 %
123.74 %
123.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 36
S&P 500 # 115




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CYBN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Takeda Pharmaceutical Company Limited-0.08%$ -0.083 millions
Seer Inc -0.29%$ -0.289 millions
Acadia Healthcare Company Inc -0.39%$ -0.390 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Celularity Inc -5.30%$ -5.300 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions


About Cybin Inc Revenue Growth Rates (CYBN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cybin Inc (CIK 1833141).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001833141-26-000046
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cybin Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.